Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 1997

View Archived Issues

Biomatrix: Q3 1997 highlights

Atrix: Q3 1997 highlights

The Liposome Company: Q3 1997 highlights

Sugen: Q3 1997 highlights

Bio-Technology General: Q3 1997 highlights

Matrix Pharmaceutical: Q3 1997 highlights

Neurobiological Technologies: Q1 1998 highlights

Sequana and Parke-Davis collaborate on drug discovery for CNS

Teijin licenses new thrombolytic from Schering AG

Peptides for autoimmune/inflammatory diseases linked to MHC molecules

Potent new fluoroquinolones described by Bayer

Novo Nordisk reports improved human insulin derivatives

Genetics Institute discloses new chemokine and its production

Lefradafiban: oral prodrug for profound and sustained inhibition of platelet aggregation

MCI-186: Mitsubishi Chemical's new candidate for acute stroke

New glycine-site NMDA partial agonist from ADIR

KGF fragments from Chiron display wound-healing activity

MMP inhibitors reported by ProScript

Zaprinast potentiates beneficial effects of inhaled NO in hypoxic pulmonary hypertension

New camptothecin analogues synthesized at U of Michigan

New alpha2-adrenoceptor agonists from Synaptic

Antihypertensive effects reported for kallikrein gene therapy

Labeling changes for Rezulin; FDA and manufacturer recommend liver function tests

New avenue opened for the treatment of congestive heart failure

New technology for BPH enters clinical trials in U.S.

Karo Bio/Merck & Co. form strategic alliance related to ER receptors

Theratechnologies and Chiron join forces against AIDS

NPS and SmithKline Beecham extend osteoporosis agreement